Hjem › Burkitts lymfom › Connecticut
Kliniske studier for Burkitts lymfom i Connecticut
7 studier for Burkitts lymfom søker deltakere på steder i Connecticut.
Byer i Connecticut
Offisiell studietekst (engelsk)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
RekruttererFase 2
366 Days – 46 Years · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Yale University, New Haven
RekruttererFase 3
Alder 18 til 39 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Yale University, New Haven
RekruttererFase 2
365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Yale New Haven Hospital ( Site 1012), New Haven
RekruttererFase 1/2
6 Months – 25 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06395103A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Connecticut Children's Medical Center, Hartford
RekruttererFase 2
Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Yale University School of Medicine, New Haven
RekruttererFase 2
Alder 1 til 25 · Alle kjønn · Oppdatert 4. mai 2025 · NCT03509961Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.